RLMD

Rating neutralTentativeAI Memo

Relmada Therapeutics

As of 2026-10-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

NDV-01 IND submission • 2026-12-31

Base target: $3 / p=50% prob

Biggest risk

NDV-01 manufacturing remains the key gate, while sepranolone has a separate delivery-system task. Q2 R&D expense rose to $8.4 million from $2.8 million a year earlier, and operating cash use rose to $9.6 million from $6.4 million. The September 8-K also reports the end of the Chief Medical Officer–Urology's employment. These factors warrant an execution discount. [#SEC-8K-2026-08-06] [#8-K-2026-09-08]

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Timely IND filings and subsequent trial starts could make the pipeline more investable. Relmada reported $217.7 million in cash, cash equivalents and short-term investments at June 30, 2026, and expects funding through 2029, including completion of RESCUE. That runway is management's projection, not a guarantee. [#SEC-8K-2026-08-06]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-25

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

NDV-01 Phase 3 RESCUE initiation
Timely IND filings and subsequent trial starts could make the pipeline more investable.
Relmada reported $217.7 million in cash, cash equivalents and short-term investments at June 30, 2026, and expects funding through 2029, including completion of RESCUE.

BearKey bullets

Low coverage, loose peers, and unavailable analyst-revision data limit valuation confidence.
NDV-01 GMP manufacturing and CMC execution could delay the targeted year-end IND filing.
[#SEC-8K-2026-08-06]

WatchKey bullets

NDV-01 IND submission

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $3 (p=50%)

Target spread vs base: +86% / -44%

Scenario probabilities

Bull Target: $6 (p=20%)Base Target: $3 (p=50%)Bear Target: $2 (p=30%)

Commentary

Cautious, milestone-driven monitoring view. The August company release supports the development timetable and cash position, while the September 8-K confirms a leadership departure. [#SEC-8K-2026-08-06] [#8-K-2026-09-08] The $3.27 anchor is dated October 23; a verified recent price reaction, analyst revisions, options data, short interest, employee ratings, and sufficient social coverage were not supplied. Zero-valued sentiment fields denote unavailable measurements, not neutral observations. Low coverage and a negative deterministic prior limit conviction.

As of 2026-10-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

NDV-01 Phase 3 RESCUE initiation

Scenarios

Bull Target (Scenario probability)

$6 / p=20% prob

Base Target (Scenario probability)

$3 / p=50% prob

Bear Target (Scenario probability)

$2 / p=30% prob

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
NDV-01 IND submission
Relmada targets a year-end 2026 IND filing for NDV-01, with GMP manufacturing and CMC work still the immediate execution gate. A filing could reduce uncertainty; another delay would weaken the near-term thesis. Probability and price impact are analyst estimates, not company guidance. [#SEC-8K-2026-08-06]
Prob 50.00% • Move 25.00% • Priced-in 35.00%
EVENT2026-12-31
Sepranolone IND submission
Relmada targets a year-end 2026 sepranolone IND filing for a planned Phase 2 Prader-Willi syndrome study. The company identified completion of the pre-filled syringe delivery system as the remaining formulation step. Estimates are conditional on execution. [#SEC-8K-2026-08-06]
Prob 50.00% • Move 10.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

NDV-01 Phase 3 RESCUE initiation
2027-03-31
Relmada plans to initiate RESCUE after IND clearance and says trial sites are engaged. March 2027 is a monitoring estimate, not a company-promised start date; manufacturing or regulatory delays could push enrollment later. [#SEC-8K-2026-08-06]
Prob 40% • Move 20% • Priced-in 25%

Risks

Low coverage, loose peers, and unavailable analyst-revision data limit valuation confidence.
NDV-01 GMP manufacturing and CMC execution could delay the targeted year-end IND filing. [#SEC-8K-2026-08-06]
Rising R&D spending and operating cash use could shorten management's projected runway if development costs exceed plan. [#SEC-8K-2026-08-06]
Sepranolone's delivery-system completion and both programs' IND clearance remain prerequisites to planned studies. [#SEC-8K-2026-08-06]
The Chief Medical Officer–Urology's employment ended September 3, 2026; the filing does not establish a resulting program delay. [#8-K-2026-09-08]

Peers

Symbol	Summary
CAPR	Similarly sized clinical-stage biotech; useful for comparing milestone-driven volatility, but its programs are not a direct NDV-01 valuation benchmark.
ENTA	Similarly sized life-sciences company with a different pipeline; useful for financing and clinical-event risk context, not an indication-matched peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-25

Loading AI feed…

Symbol

Summary

CAPR

Similarly sized clinical-stage biotech; useful for comparing milestone-driven volatility, but its programs are not a direct NDV-01 valuation benchmark.

ENTA

Similarly sized life-sciences company with a different pipeline; useful for financing and clinical-event risk context, not an indication-matched peer.